Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNBELIEVABLE: 3 | History Defined

Mayo Clinic Q and A: How to manage symptoms of liver disease

DEAR MAYO CLINIC: My husband is 45 and has lived with irritable bowel syndrome for many years. He was recently diagnosed with primary sclerosing cholangitis. Are these two conditions related? We were told a liver transplant was likely in the future. Do all people require a transplant? Are other treatments…

Tribune News Service

Applied Molecular Shares Tumble After Disappointing Data From Mid-Stage Ulcerative Colitis Study

Applied Molecular Transport Inc (NASDAQ: AMTI) has

Benzinga

Firefighter suffering from 'invisible illness' has to go to the toilet 30 times a day

Catherine Hopkins started suffering swollen joints, belly pain and chronic fatigue at the age of 27 and was diagnosed with ulcerative colitis which has had a major impact on her quality of life

Daily Mirror

From analysis to the latest developments in health,
read the most diverse news in one place.

Seres Therapeutics Touts New Safety Data, Plans First FDA Approval For Microbiome Drug

Seres Therapeutics Inc (NASDAQ:MCRB) announced confirmatory results from ECOSPOR IV, an open-label study for SER-109 to prevent recurrent C. difficile infection (rCDI). The overall safety profile observed in ECOSPOR IV through 24 weeks indicated that SER-109 was well tolerated. The ECOSPOR III and ECOSPOR IV studies conclude the SER-109 Phase 3 development program. In ECOSPOR…

Benzinga

Lanarkshire student, 23, dies 13 days after cancer diagnosis as twin sister demands answers

Ryan Brown's family are planning to submit a formal complaint to NHS Lanarkshire as they believe he received "a neglectful lack of care".

Glasgow Live

Young Scot dies from bowel cancer 13 days after diagnosis as twin sister hits out at 'lack of care'

Ryan Brown's sister Hope believes there were multiple missed opportunities to diagnosis her sibling and is calling for more frequent testing for patients with ulcerative colitis.

Daily Record

Lilly Touts Encouraging Mirikizumab Data In Ulcerative Colitis Maintenance Setting

Eli Lilly And Co (NYSE:LLY) announced a data readout for the Lucent-2 Phase 3 study of mirikizumab after 52 weeks. The trial enrolled patients with ulcerative colitis who had initially responded to mirikizumab in a 12-week Lucent-1 study. The primary endpoint was clinical remission, with 49.9% of participants in the mirikizumab arm reaching…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Pfizer's Ulcerative Colitis Candidate Shows Remission In Over 30% Of Patients In Pivotal Studies

Pfizer Inc (NYSE:PFE) has announced detailed results from two pivotal studies from ELEVATE UC Phase 3 program evaluating etrasimod for active ulcerative colitis (UC). The drug, etrasimod, was Pfizer's key asset in its $6.7 billion deal for Arena Pharmaceuticals last year. UC is an inflammatory bowel disease that affects around 3.8 million people in North…

Benzinga

Surrozen Commences Phase 1 Study of SZN-1326 In Ulcerative Colitis

Surrozen, Inc. (NASDAQ: SRZN) announced that the first patient has been dosed in the Phase 1 clinical trial to evaluate its drug candidate SZN-1326 for the potential treatment of moderate to severe ulcerative colitis.

Benzinga

New treatment available on NHS to ulcerative colitis sufferers in Scotland

The Scottish Medicines Consortium has approved the new tablet called filgotinib.

The Independent UK

The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

Connect Biopharma Stock Plunges As Ulcerative Colitis Candidate Flunks In Mid-Stage Study

Connect Biopharma Holdings Limited (NASDAQ:CNTB) announced topline results at 12 weeks from its Phase 2 trial for CBP-307 (CBP-307CN002) for ulcerative colitis. CBP-307 0.2 mg demonstrated a numerical reduction for the primary endpoint of least squares mean change from baseline in adapted Mayo Score at Week 12 that did not meet statistical significance. …

Benzinga

Why Protagonist Therapeutics Shares Are Crashing Today

Protagonist Therapeutics Inc (NASDAQ:PTGX) announced topline results from the Phase 2 IDEAL study of PN-943 in moderate-to-severe ulcerative colitis (UC) patients. 159 patients with moderate-to-severe active UC were randomized to either twice daily (BID) with 450 mg or 150 mg PN-943, or placebo, for 12 weeks. While the 450 mg BID dose did…

Benzinga

The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Edinburgh Live

Teen who was 'too self-conscious' about symptoms diagnosed with chronic illness

Megan McNeil was suffering from extreme fatigue, weight loss and visiting the toilet 15-20 times an hour before being diagnosed with Ulcerative Colitis, with the now 21-year-old opening up about her journey

Daily Mirror

Woman diagnosed with chronic illness after years of embarrassment about symptoms

Megan McNeil, 21, was diagnosed with Ulcerative Colitis after she experienced symptoms such as passing blood when going to the bathroom

Benzinga

Protagonist Therapeutics Topline Data from Phase 2 IDEAL Study of PN-943 (450 mg BID) Miss Primary Endpoint

Protagonist Therapeutics (NASDAQ: PTGX) announced top-line results from the Phase 2 IDEAL clinical study evaluating PN-943 in patients with moderate-to-severe ulcerative colitis (UC).

Benzinga

Applied Molecular's AMT-101 Shows Favorable Clinical Activity, Safety Profile In Inflammatory Bowel Disease

Applied Molecular Transport Inc (NASDAQ:AMTI) announced Phase 2 topline results from the FILLMORE monotherapy trial for AMT-101 in chronic pouchitis. Pouchitis is inflammation in the lining of a pouch created during surgery to treat ulcerative colitis or certain other diseases. The trial demonstrated that 36.4% (8/22) of patients achieved stool frequency response. Rapid…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Gossamer Bio Pulls Plug On Mid-Stage Ulcerative Colitis Program

Gossamer Bio Inc (NASDAQ:GOSS) shares are falling after announcing topline results from its Phase 2 SHIFT-UC Study trial of GB004 in patients with mild-to-moderate active ulcerative colitis (UC). Neither GB004 treatment arm met the primary or secondary endpoints at week 12. Gossamer will terminate the ongoing treat-through and open-label extension portions of the…

Irish Mirror

Young woman diagnosed with chronic illness after feeling embarrassed about symptoms

Megan McNeil was diagnosed with Ulcerative Colitis after she experienced symptoms such as passing blood when going to the bathroom

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Glasgow Royal Infirmary

Read news from The Economist, FT, and more,
with one subscription

Topics

Irritable Bowel Syndrome

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.